Changes in Hong Kong stocks | Cinda Biotech (01801) opened more than 2%, and product revenue in the first half of the year exceeded 8.2 billion yuan, up more than 55% year-on-year

The Zhitong Finance App learned that Cinda Biotech (01801) opened more than 2% higher. As of press release, it rose 2.48% to HK$88.85, with a turnover of HK$138.30,500.

According to the news, Cinda Biotech announced that in the first half of the year, product revenue recorded more than 8.2 billion yuan, an increase of more than 55% over the previous year. Product revenue in the second quarter exceeded 4.3 billion yuan, a year-on-year increase of about 60%. This strong performance reflects the continued effectiveness of the company's “two-wheel drive” strategy. Core products such as Siniermax®, Simpilla®, and Xinbimin® performed well and became an important driving force for revenue growth.

In addition, the company's leadership in the field of oncology continues to be consolidated. The market penetration rate of the 5 new tyrosine kinase inhibitors included in the national health insurance catalogue continues to increase, and revenue volume is accelerating. The company also successfully expanded into the field of breast cancer treatment and reached a commercial cooperation with Eli Lilly's Choice® in mainland China, laying the foundation for subsequent breast cancer pipeline development and market expansion.